200.80
+1.67%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xvivo Perfusion
Its shares trade on Nasdaq Stockholm under the ticker XVIVO.ST. It has been listed since 8 October 2012. In the fiscal year to 31 December 2025, it reported revenue of SEK 812.2m and net income of SEK 25.2m. At that date it held total assets of SEK 2.37bn and shareholders' equity of SEK 2.11bn.
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Oct 2012
- Employees
- 59
- Website
- xvivoperfusion.com ↗
Leadership
Pay as last reported
- Mr. Gosta JohannessonChairman of the BoardSEK 515,000
- Mr. Christoffer RosenbladChief Executive OfficerSEK 782,000
- Ms. Lena HagmanDeputy Chief Executive Officer, Chief Operating Officer
- Mr. Kristoffer NordstroemChief Financial Officer
- Ms. Ylva VihojSenior Vice President of Human Resources
- Mr. Johan HolmstroemSenior Vice President, Commercial Europe & RoW, since 2024
- Mr. Mark ReadeSenior Vice President, North America
- Ms. Jaya TiwariSenior Vice President, Clinical & Regulatory Affairs, North America
- Dr. Andreas WallinderChief Medical Officer
- Mr. Goeran DellgrenIndependent DirectorSEK 260,000
- Mr. Lars HenrikssonIndependent DirectorSEK 260,000
- Ms. Lena HoeglundIndependent DirectorSEK 260,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 63
- Social
- 92
- Governance
- 48
- Direct emissions (scope 1)
- 61.804 t
- Energy emissions (scope 2)
- 92.706 t
- Value chain emissions (scope 3)
- 15,296.49 t
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xvivo Perfusion AB has several strengths that contribute to its success and competitive advantage. Firstly, the company possesses advanced technologies and expertise in organ and lung perfusion systems, allowing them to effectively address the growing demand for organ transplantation. Secondly, Xvivo Perfusion AB has a strong global presence and a well-established network of distribution channels, enabling them to reach international markets efficiently. Lastly, the company has a talented and dedicated workforce, which plays a crucial role in driving innovation and maintaining superior product quality.
Weaknesses
- Despite its strengths, Xvivo Perfusion AB also faces certain weaknesses that need to be addressed. One notable weakness is the company's reliance on a limited number of key customers, potentially exposing them to financial risks if these customers choose to seek alternative suppliers. Additionally, Xvivo Perfusion AB may face challenges in securing regulatory approvals for their products in certain markets, which can hinder their ability to expand globally. Lastly, the company could benefit from enhancing their marketing efforts to further increase brand awareness and capture larger market share.
Opportunities
- There are several opportunities available for Xvivo Perfusion AB to capitalize on. Firstly, the growing demand for organ transplantation presents a significant market opportunity for the company to expand its customer base and increase sales. Secondly, advancements in medical research and technology provide an opportunity for Xvivo Perfusion AB to develop and introduce innovative perfusion systems with improved functionalities, setting them apart from competitors. Lastly, strategic partnerships and collaborations with hospitals, research institutions, and pharmaceutical companies can provide access to complementary expertise and resources, fostering innovation and driving market growth.
Threats
- Xvivo Perfusion AB faces several threats that could impact its business. Firstly, intense competition within the medical technology industry poses a threat, as other companies with similar perfusion solutions may attempt to gain market share. Additionally, regulatory changes and stringent approval processes in certain countries can hinder Xvivo Perfusion AB's ability to enter new markets or cause delays in product launches. Furthermore, economic downturns or financial instability in key markets can impact customer demand for organ and lung perfusion systems. Lastly, disruptive technologies or breakthroughs in alternative transplantation methods could pose a long-term threat if Xvivo Perfusion AB fails to adapt and evolve its offerings accordingly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.